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Severe acute respiratory syndrome
coronavirus 2‑induced acute aortic occlusion:
a case report
Artem Minalyan*, Franklin L. Thelmo, Vincent Chan, Stephanie Tzarnas and Faizan Ahmed

Abstract
Background: Severe acute respiratory syndrome coronavirus 2 infection can lead to a constellation of viral and
immune symptoms called coronavirus disease 2019. Emerging literature increasingly supports the premise that
severe acute respiratory syndrome coronavirus 2 promotes a prothrombotic milieu. However, to date there have been
no reports of acute aortic occlusion, itself a rare phenomenon. We report a case of fatal acute aortic occlusion in a
patient with coronavirus disease 2019.
Case report: A 59-year-old Caucasian male with past medical history of peripheral vascular disease presented to the
emergency department for evaluation of shortness of breath, fevers, and dry cough. His symptoms started 5–7 days
prior to the emergency department visit, and he received antibiotics in the outpatient setting without any effect. He
was found to be febrile, tachypneic, and hypoxemic. He was placed on supplemental oxygen via a non-rebreather
mask. Chest X-ray showed multifocal opacifications. Intravenous antibiotics for possible pneumonia were initiated.
Hydroxychloroquine was initiated to cover possible coronavirus disease 2019 pneumonia. During the hospitalization,
the patient became progressively hypoxemic, for which he was placed on bilevel positive airway pressure. D-dimer,
ferritin, lactate dehydrogenase, and C-reactive protein were all elevated. Severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction was positive. On day 3, the patient was upgraded to the
intensive care unit. Soon after he was intubated, he developed a mottled appearance of skin, which extended from
his bilateral feet up to the level of the subumbilical plane. Bedside ultrasound revealed an absence of flow from the
mid-aorta to both common iliac arteries. The patient was evaluated emergently by vascular surgery. After a discussion
with the family, it was decided to proceed with comfort-directed care, and the patient died later that day.
Discussion: Viral infections have been identified as a source of prothrombotic states due to direct injury of vascular
tissue and inflammatory cascades. Severe acute respiratory syndrome coronavirus 2 appears to follow a similar pattern, with numerous institutions identifying elevated levels of thrombotic complications. We believe that healthcare
providers should be aware of both venous and arterial thrombotic complications associated with coronavirus disease
2019, including possible fatal outcome.
Keywords: COVID-19, Coronavirus, Aortic occlusion, Thrombosis, Case report
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Background
AAO is a very rare life-threatening condition associated
with high mortality despite advances in surgical management, with a 30-day mortality rate of 21–52%. Saddle
embolus, in situ thrombosis in the setting of severe atherosclerotic disease, and occlusion of previous surgical
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constructions (for example, stents, grafts) are considered
the most common causes of AAO [1]. Abdominal aortic aneurysm (AAA) is another condition that is known
to be associated with an increased risk of AAO. It is
thought that AAA can cause AAO as there is an interruption in laminar flow leading to turbulence and an
increased risk of clot formation [2]. Multiple conditions
including malignancies, infections, and connective tissue
disorders are known to lead to hypercoagulability. Therefore, patients with said conditions are also at increased
risk of thrombotic events [3]. SARS-CoV-2 is the cause
of the current 2019–2020 pandemic. There is emerging
evidence that it is also associated with hypercoagulable
states, therefore, leading to thrombotic events [4]. Arterial thrombotic events have also been described in the literature [5, 6]. It is speculated that endovascular damage
triggers the cascade of pathologic changes that leads to
the development of arterial thrombi [7].

Case presentation
A 59-year-old Caucasian male presented to the emergency department (ED) from a nursing home for evaluation of shortness of breath, fevers, and dry cough. His
past medical history included schizophrenia, epilepsy,
and peripheral vascular disease. As per the patient, his
symptoms started 5–7 days prior to the ED visit. He was
treated in the outpatient setting with azithromycin for
concern of community-acquired pneumonia. He presented to the ED due to progressive dyspnea from his
facility where staff found the patient to be hypoxemic
with an O2 saturation in the 80s on room air. Of note, the
patient was exposed to facility residents with confirmed
SARS-CoV-2 infection. However, he tested negative for
SARS-CoV-2 infection prior to arrival.
In the ED, he was found to be febrile with oral temperature of 38.2 ℃, tachypnea at 22 breaths per minute,
and persistent hypoxemia requiring supplemental oxygen delivery via a non-rebreather mask. Physical exam
revealed no aberrations in his heart or lungs. Chest X-ray
showed bilateral airway opacities concerning for multifocal pneumonia. A complete metabolic panel (CMP) and
complete blood count (CBC) with differential revealed
lymphopenia with an absolute lymphocyte count 0.5 K/
μL (reference range 1.5–3.2). The patient was started on
intravenous antibiotics (vancomycin, cefepime, levofloxacin) for presumed bacterial pneumonia. Hydroxychloroquine was initiated to cover possible COVID-19
pneumonia. The patient was admitted to hospital. On
day 2, the patient remained hypoxemic and developed
increased work of breathing for which he was placed on
bilevel positive airway pressure (BiPAP). D-dimer, ferritin, lactate dehydrogenase, and C-reactive protein were
all elevated (Fig. 1). SARS-CoV-2 reverse transcription

Fig. 1 Trends of inflammatory markers during hospitalization

polymerase chain reaction (RT-PCR) was positive. On
day 3, the patient was upgraded to the intensive care unit
(ICU) where he was later intubated. Soon after he was
intubated, he developed a mottled appearance of skin
that extended from his bilateral feet up to the level of the
subumbilical plane. Pulses were unable to be detected
both via palpation and Doppler. Bedside ultrasound was
performed, and absence of anterograde flow was noted
from the mid-aorta down to both common iliac arteries (Fig. 2); a deep venous thrombosis (DVT) in the left
femoral vein was also revealed. The patient became hypotensive in the ICU with mean arterial pressure (MAP) of
50 mmHg. He was started on a norepinephrine drip for
pressure support. Given hemodynamic instability and
the high likelihood of venous thromboembolic event, the
decision was made to start thrombolytic therapy with tissue plasminogen activator (tPA) of 50 mg intravenously
once as well as systemic anticoagulation with a heparin
drip. The patient was evaluated emergently by the vascular surgery team. The patient was deemed too unstable
to be taken for computed tomography (CT) angiography.
No AAA was identified in the patient. After a discussion
with the family, it was decided to proceed with comfortdirected care, and the patient died later that day.

Discussion and conclusions
SARS-CoV-2, first reported in Wuhan, China on 31
December 2019, is a virus that has caused a pandemic
as declared by the World Health Organization (WHO)
in March 2020 [8, 9]. As of mid-May, there are almost
4,500,000 reported cases worldwide while the USA has
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Fig. 2 Ultrasound Doppler imaging of patient’s aorta and iliac arteries (a) proximal aorta, (b) mid aorta, (c) left common iliac artery, and (d) right
common iliac artery

the highest number of cases (almost 1,500,000). It is
estimated that at least 300,000 people have died so far
because of COVID-19 [10]. SARS-CoV-2 belongs to
the genus Betacoronavirus [11]. There are four lineages
within the genus: A (HCoV-OC43, HCoV-HKU1)—frequently found in patients with common cold; B (SARSCoV and SARS-CoV-2)—cause of SARS and COVID-19
pandemics, respectively; C (Middle East respiratory
syndrome-related coronavirus (MERS-CoV)—cause of
MERS outbreak; D (CoV-HKU9)—found only in animals [12]. They are all enveloped positive-sense singlestranded ribonucleic acid (RNA) viruses. Notably, both
SARS-CoV and SARS-CoV-2 use the same receptor,
angiotensin-converting enzyme 2 (ACE2), for cell entry
[13]. It is estimated that SARS-CoV-2 is more contagious than seasonal influenza on the basis of their differing R0 values, with influenza being estimated at 1.3 and
SARS-CoV-2 being estimated at 2.5 [14, 15]. The majority of patients with COVID-19 have nonsevere symptoms and do not require hospitalization. In hospitalized

patients, it has been shown that about 15% of patients
are treated in the ICU. Importantly, in a study from New
York, 12% of hospitalized patients were reported to be
placed on mechanical ventilation. In ventilated patients,
the survival was found to be only 12% [16]. Despite the
availability of several therapeutic agents being studied
for COVID-19, all remain investigational, and supportive treatment is considered the therapeutic mainstay in
affected patients.
Various infections have been known to be associated
with an increased risk of thrombosis. There are several
possible explanations of thrombosis in infections: (1)
activation of platelets, (2) shift of the coagulation cascade towards procoagulant state, (3) stasis in the setting
of prolonged immobilization, and (4) vascular endothelial
dysfunction. The above-mentioned changes are consistent with Virchow’s triad, which is widely recognized as
the pathophysiological foundation of venous thrombosis
formation [17]. It is suggested that the inflammationinduced thrombosis from an infectious trigger has more
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procoagulant potential when compared with noninfectious inflammatory conditions. Viral models in animals
of infections such as Ebola, influenza, and human immunodeficiency virus (HIV) have shown that viruses can
induce the expression of tissue factor in phagocytes that
in turn activate the extrinsic pathway of the coagulation
cascade [18]. The activation of macrophages has been
shown to induce deposition of fibrin in multiple organs
[19]. In addition, in mice infected with a lethal dose of
influenza virus leading to acute respiratory distress syndrome (ARDS), increased platelet aggregation, endothelial damage, and release of inflammatory cytokines
manifesting as the presence of diffuse pulmonary microvascular thrombi have been observed [20].
In patients with COVID-19, it was estimated that up to
a third of critically ill patients develop thromboembolic
events [21]. Interestingly, life-threatening thrombosis
has been noted to occur frequently in affected patients
despite full-dose anticoagulation [22]. In all hospitalized
patients with COVID-19, multiple laboratory tests are
obtained initially. High fibrinogen and D-dimer can be
indicative of procoagulant state. Fibrinogen (factor I) is
a plasma protein involved in both primary and secondary hemostasis. Of note, there is some evidence that very
high levels of fibrinogen can act as antithrombin and,
therefore, compromise clot stability [23]. D-dimer is a
protein fragment that is formed after the degradation of
factor XIIIa cross-linked fibrin. It is cleared in the liver
and spleen. Therefore, in patients with asplenia and liver
failure, D-dimer can circulate in blood for a prolonged
time [24]. Detection of normal levels of D-dimer is helpful in ruling out venous thromboembolism (VTE). In
contrast, high levels of D-dimer are nonspecific and can
be seen in patients with VTE as well as malignancy, sepsis, and other inflammatory conditions. It was reported
that patients with very high levels of D-dimer (> 5000
µg/L) have high predictive value for serious disease,
including VTE (40.1%), cancer (28.9%), sepsis (24.4%),
and complicated trauma/surgery (24.4%) [25]. Imaging tests [bilateral compression ultrasonography of the
legs and CT pulmonary angiography (CTPA)] are diagnostic tests of choice in patients with suspected VTE.
In patients hospitalized with COVID-19, imaging tests
such as CTPA may not always be readily available given
healthcare strain due to the ongoing pandemic. Therefore, quantitative assessment of D-dimer is widely used
to assess the risk of VTE and initiate empiric treatment
with anticoagulation in high-risk patients. Of note, there
are no universally accepted guidelines on D-dimer trends
and the decision on anticoagulation in affected patients.
Those decisions are mostly made based on physician discretion and hospital protocol.
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In general, AAO is an extremely rare condition. Its true
incidence is unknown, with numbers being obtained
from case series. This is in contrast to arterial thrombosis leading to acute limb ischemia with an incidence rate
of 1.5 per 100,000 person-years [26]. In 2019 the Swedish Nationwide Vascular Database reviewed patients with
AAO from 1994 to 2014 and estimated an incidence rate
of 3.8 per 1 million person-years, with the average individual being 70 years of age, presenting with acute limb
ischemia with a history of cardiac disease, hypertension,
and current smoking [1]. Le Berre et al reported a nonfatal case of acute aortic thrombosis in a 71-year-old male
with COVID-19. A CT angiogram of the aorta revealed
an accidental finding of a free-floating thrombus in the
descending aorta. The patient was treated with therapeutic enoxaparin [6]. While our case likely highlights
the first reported case of SARS-CoV-2-induced AAO, the
association between viral infection and arterial thrombi
has been previously identified [27, 28]. Unlike venous
thromboembolic events proposed to be mostly related
to hemostasis and coagulopathy, it has been postulated
that arterial thrombus is driven more so by endovascular
injury rather than stasis given the dynamic nature of the
arterial wall [7].
Treatment options for acute arterial thrombosis include anticoagulation, thrombolysis, mechanical thromboembolectomy, and clot bypass. The choice
of therapy depends on the timing and the setting of the
artery involved, such as a coronary artery or a cerebral
artery. Acute treatment with thrombolytics that cause
the degradation of fibrin such as tPA is one such example
where the timing of arterial thrombosis is crucial in its
use [29]. Other common medical therapies include antiplatelet agents such as cyclooxygenase inhibitors, P2Y12
inhibitors, glycoprotein IIb/IIIa inhibitors, and proteaseactivated receptor 1 inhibitors [30]. Newer studies are
beginning to investigate the utility of direct oral anticoagulants such as apixaban and rivaroxaban in peripheral
arterial disease and other arterial thromboses [31, 32].
Acute aortic thrombosis, as compared with coronary,
cerebral, and peripheral arterial thrombosis, is rare.
There are no specific guidelines on management of acute
aortic thrombosis as literature is mostly relegated to case
reports.
In summary, the nascent COVID-19 pandemic has
raised global concern regarding the role of viral infection and its effect on hypercoagulability. There is ongoing
debate as to whether individuals should be actively monitored for severe thromboembolic events due to COVID19 and if the initiation of therapeutic anticoagulation is
warranted. Our case demonstrates that life-threatening
hypercoagulability of large arterial vessels leading to
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occlusion can develop in patients with COVID-19, leading to hemodynamic collapse.
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